Compare Ascendis Pharma A/S (ASND) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs ABRDN Physical Gold Shares ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while ABRDN Physical Gold Shares ETF trades at $38.76. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals.
| ASND | SGOL | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $277.18 | $51.41 |
52-Week Low | $163.32 | $31.18 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SGOL, a gold-focused US stock, trades at $39.12, down 0.28% on the day amid a broader bearish technical signal. The stock faces headwinds from declining gold prices, which have fallen over 25% from recent highs, and outflows from gold ETFs as investors react to Federal Reserve policy expectations. Despite this, central bank buying provides underlying support, with entities like Poland and China increasing reserves, highlighting a divergence between speculative selling and long-term institutional demand.
The outlook for SGOL remains cautious near-term due to gold price volatility and hawkish Fed sentiment, but structural support from central bank diversification offers a potential floor. Risks include further ETF liquidations and rising Treasury yields, while opportunities lie in sustained institutional accumulation if macroeconomic uncertainty persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
